Vitamin D and Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a functional GI disorder affecting 10–15% of adults worldwide. Vitamin D deficiency is significantly more common in IBS patients than in matched controls, and small supplementation trials have reported meaningful improvements in symptom severity scores.
Deficiency prevalence
A 2018 systematic review pooled 7 studies and found IBS patients had a 3.6-fold higher odds of vitamin D deficiency than controls, and lower mean 25(OH)D (weighted mean difference −7.7 ng/mL). Whether deficiency causes IBS or IBS-associated restrictive eating causes deficiency is unclear from observational data.
Supplementation trials
- Jalili 2019 (Iran RCT) — 88 IBS patients; 50,000 IU cholecalciferol every 2 weeks for 6 months significantly improved IBS-SSS symptom score and quality of life vs placebo.
- Abbasnezhad 2016 — 88 IBS patients; 50,000 IU every 2 weeks for 6 weeks improved global IBS symptom score, quality of life, and disease severity.
- Williams 2022 (UK VIBRANT trial) — 135 IBS patients; 3,000 IU/day for 12 weeks: 25(OH)D rose but no significant symptom improvement.
- 2022 meta-analysis — pooled significant reduction in IBS-SSS score, particularly with intermittent high-dose bolus regimens; less clear with daily standard dosing.
Why the mixed results
IBS is heterogeneous — IBS-C, IBS-D, IBS-M subtypes have different biology and likely respond differently. Placebo response rates in IBS trials are notoriously high (30–40%). Studies with the largest signal used intermittent high-dose cholecalciferol; whether this reflects true dose-response or trial-specific artefact is unclear.
Practical guide
- Test 25(OH)D — most IBS patients would benefit from knowing their level.
- Correct any deficiency with 2,000–4,000 IU/day for 8–12 weeks.
- If already sufficient, additional supplementation is unlikely to help IBS symptoms.
- Vitamin D is an adjunct to evidence-based IBS interventions — dietary trials (low-FODMAP), soluble fibre, antispasmodics, gut-directed hypnotherapy, and (subtype-specific) rifaximin, linaclotide, or eluxadoline.